UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report:
(Date of earliest event reported)
(Exact name of registrant as specified in its charter)
| (State of other jurisdiction | (Commission | (IRS Employer | ||
| of incorporation) | File Number) | Identification No.) |
(Address of principal executive offices and zip code)
1-
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company.
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On January 25, 2022, Mr. Ronald L. Miller, Jr. (“Mr. Miller”) resigned, effective immediately, from the board of directors of Item 9 Labs Corp (the “Company”) and the board accepted Mr. Miller’s resignation on January 26, 2022. Mr. Miller’s resignation was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies, practices, or otherwise. The Company is appreciative of Mr. Miller’s decade of service to the Company as a director. Mr. Miller will continue working with the Company in a financial consulting role.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ITEM 9 LABS CORP. | ||
| Dated: February 1, 2022 | By: | /s/ Robert Mikkelsen |
| Robert Mikkelsen | ||
| Chief Financial Officer | ||
Cover |
Feb. 01, 2022 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Feb. 01, 2022 |
| Entity File Number | 000-54730 |
| Entity Registrant Name | Item 9 Labs Corp. |
| Entity Central Index Key | 0001500123 |
| Entity Tax Identification Number | 96-0665018 |
| Entity Incorporation, State or Country Code | DE |
| Entity Address, Address Line One | 2727 N 3rd Street |
| Entity Address, Address Line Two | Suite 201 |
| Entity Address, City or Town | Phoenix |
| Entity Address, State or Province | AZ |
| Entity Address, Postal Zip Code | 85004 |
| City Area Code | 833 |
| Local Phone Number | 867-6337 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Entity Emerging Growth Company | false |
-8?20$3;
M8T.P6BP^0"X99K>]9!:G